AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03462368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antimicrobial photodynamic therapy
Description: In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
Study NCT03462368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
Study NCT01888809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive preventive services
Description: Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
Study NCT01888809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and referral
Study NCT03766373 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Drug: OP0201 20mg
Description: OP0201
Study NCT03766373 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo 0mg
Description: Placebo
Study NCT02633397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
Study NCT02633397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
Study NCT02275299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
Study NCT02275299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
Study NCT02275299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
Study NCT02275299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
Study NCT04938739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained.
Study NCT04938739 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home program exercises
Description: Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
Study NCT04938739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home program exercises
Description: Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
Study NCT04251546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: p2PSA
Description: p2PSA test(for calculation of PHI)
Study NCT04251546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic parameters
Description: Ultrasonic parameters(TPV)
Study NCT04251546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal prostate biopsy
Description: Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
Study NCT02279992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil
Study NCT02279992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study NCT02279992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT03591432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)
Description: Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
Study NCT03591432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facemask ventilation
Description: Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
Study NCT00110955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Q3W 300 mcg darbepoetin alfa
Study NCT00110955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Q3W dosing of placebo
Study NCT04115956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan-Flufenamide (Melflufen)
Description: Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
Study NCT04115956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
Study NCT02923817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection
Study NCT02660112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin
Description: 25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
Study NCT02748902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate 0.05% gel
Description: Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
Study NCT04382768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Hypertonic ibuprofen
Description: Standard of care plus lipid ibuprofen 50mg tid
Study NCT00787813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
Study NCT00787813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03626025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Spaced learning
Description: Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
Study NCT01660919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01660919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Study NCT04588519 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System
Description: Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
Study NCT03084198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hiHep Bioartificial Liver Support System
Description: Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
Study NCT03084198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care for ALF
Description: A standard of care for subjects with acute liver failure.
Study NCT01974453 — intervention group
Intervention type: RADIATION
Intervention: Radiation dose
Description: Radiation dose adsorbed by operators
Study NCT02825277 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler
Description: acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
Study NCT00944996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI; SNRI; TCA
Description: Tablets or Pills, 1 or 2 per day, more than 2 month
Study NCT03494621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protecting Babies While they Sleep Curriculum
Description: The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
Study NCT04387903 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical re-interventionafter pancreaticoduodenectomy
Description: Mandatory surgical management of complications after pancreatico-duodenectomy through peritoneal lavage, draiange, repair of fistula, completion pancreatectomy, control of bleeding, bowel resection, and feeding jejunostomy.
Study NCT01586533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoenasa-1:4
Description: Zoenasa Rectal Gel (4.0g mesalamine \[5-ASA\], 1.0g N-acetylcysteine \[NAC\]; 60ml)
Study NCT01586533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine Enema
Description: Mesalamine Rectal Suspension Enema (4.0g mesalamine \[5-ASA\], 60ml)
Study NCT02712307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin
Study NCT02712307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin
Study NCT03586141 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pronto® hemoglobin measurement tool
Description: All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
Study NCT02189369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 3 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
Study NCT02189369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Description: Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
Study NCT03628183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolysate Infant Formula 1
Description: Feed ad lib
Study NCT03628183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrolysate Infant Formula 2
Description: Feed ad lib
Study NCT00985283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive home visit
Description: in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
Study NCT00985283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: minimal intervention
Description: provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
Study NCT00487552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Magnetic Anastomosis Device (MAD) with Stent
Description: Gastro-jejunal anastomosis
Study NCT01990313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S
Description: The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
Study NCT02264236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P10s-PADRE vaccine
Description: P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5.
Study NCT02406274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Spectral Mammography (CESM)
Description: Women presenting to MSKCC with a palpable abnormality within the breast either self palpated \& or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) \& record their findings. They will then interpret the CESM \& record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding \& will either be called negative \& followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
Study NCT03418181 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Haemodialysis
Description: Thrice weekly dialysis.
Study NCT03418181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incremental dialysis
Description: Individualised dialysis dose according to native kidney function.
Study NCT02893488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/ABC/3TC FDC DISPERSIBLE TABLET
Description: DTG/ABC/3TC FDC dispersible tablet
Study NCT02893488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZICOM (ABC/3TC)
Description: EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side.
Study NCT02893488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVICAY (DTG)
Description: TIVICAY will be available as white, round, biconvex tablets
Study NCT00332488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere Insulin
Description: Inhalation, 15U/30U, prandial
Study NCT00780624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
Study NCT00780624 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
Study NCT02055274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Study NCT02055274 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupro
Study NCT03062995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula with added synbiotics
Description: Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
Study NCT03062995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Infant formula
Description: Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
Study NCT04494594 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Drinks:Ration app
Description: Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
Study NCT04494594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drinks:Ration app
Description: Drinks:Ration (www.drinksration.app; formerly called InDEx) app has been developed following the Medical Research Council Complex Intervention Guidelines and using co-design methodology by the King's Centre for Military Health Research (at King's College London) and the University of Liverpool, supported by experts in smartphone app development, epidemiology, addiction psychiatry, and military mental health. The app is designed to support veterans drinking at a hazardous or harmful level by providing detailed advice and support over a minimum of 28-day period. The app is theoretically underpinned to enhance participants motivation and self-efficacy in modifying their alcohol consumption by means of Behaviour Change Theory in the content displayed, and the messaging sent to participants.
Study NCT02800941 — intervention group
Intervention type: DRUG
Intervention: Oral anticoagulant treatment
Description: The treatment is delivered according to the usual practice.
Study NCT03489941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EM-100
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
Study NCT03489941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaditor®
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
Study NCT03489941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
Study NCT04548388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: A specialist physiotherapist in neurological rehabilitation provided the Bobath approach individually to each patients in both groups. Bobath approach included 3 days a week over a total of 12 sessions for four weeks. The Bobath approach consisted of about individual one hour session.~In addition to the Bobath approach, the subjects in the study group received WBV for 20 minutes a day, 2 days a week. The frequency of the device was increased by 5 Hz every week, starting the treatment with 30 Hz. Whole body vibration application was performed on a platform (Power Plate Pro5®) that provides vertical vibration. Two different practice positions were chosen as standing and semi-squatting. In order to prevent muscle fatigue, the set consisting of 1 minute of application - 1 minute of rest in each position was applied for a total of 10 minutes with 5 repetitions
Study NCT04026932 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Listening to unmodified music
Description: Listening to unmodified music for at least 2 hours a day
Study NCT04026932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to modified tinnitus relieving sound
Description: Listening to modified tinnitus relieving sound for at least 2 hours a day
Study NCT03327961 — intervention group
Intervention type: DEVICE
Intervention: scaffold
Description: implantation of scaffold (eg Magmaris, Desolve, Others)
Study NCT02893423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
Study NCT02614131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2599666
Description: Administered SC
Study NCT02614131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered IV
Study NCT02614131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Administered SC
Study NCT02614131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Administered IV
Study NCT00636636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended Release tablets
Description: Once-Daily; 300 mg and 600 mg tablets
Study NCT00636636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily; 300 mg and 600 mg tablets
Study NCT01499641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Epidural methylprednisolone 40 mg or none
Study NCT01499641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Epidural methylprednisolone 40 mg or none
Study NCT00962936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011
Description: CT-011